Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt)
Jonathan Canaani,Myriam Labopin,Xiao-Jun Huang,Fabio Ciceri,Maria Teresa Van Lint,Benedetto Bruno,Stella Santarone,Jose L. Diez-Martin,Didier Blaise,Simona Sica,Depei Wu,Mohamad Mohty,Arnon Nagler
DOI: https://doi.org/10.1016/j.bbmt.2017.12.684
2018-01-01
Biology of Blood and Marrow Transplantation
Abstract:Background: Assessment of minimal residual disease (MRD) is actively transitioning into the mainstream routine evaluation of response to therapy and prognostication schemes in patients (pts) with acute myeloid leukemia (AML). While it is well established that pre-transplant positive MRD studies predict for relapse and transplantation outcome in pts transplanted either from matched sibling donors or matched unrelated donors, it is currently unknown whether MRD has comparable prognostic value for pts undergoing haploidentical stem cell transplantation (haplo-SCT). Methods: To analyze the prognostic impact of MRD in haplo-SCT, we performed a retrospective analysis using the ALWP multicenter registry. All adult AML pts with known MRD status at transplant who underwent a first T-cell replete related haplo-HCT in first or second complete remission from 2006 to 2016 were included. Results: Three hundred ninety-three pts of whom 265 were MRD negative and 128 were MRD positive prior to transplant met the study inclusion criteria. Median follow-up period was 26 and 15 months for MRD negative and positive pts, respectively. Compared to MRD positive pts, MRD negative pts were more likely to be NPM1wt (65% vs. 46%; P = .01) as well as harbor poor risk cytogenetics (15% vs. 7%; P < .001). Both groups of pts did not differ to a significant degree in terms of patient age, performance status, FLT3-ITDstatus, conditioning intensity, and post-transplant immunomodulation strategy (namely, use of post-transplant cyclophosphamide or anti-thymocyte globulin). In multivariate analysis, MRD negative patients experienced lower relapse incidence [Hazard ratio (HR) = .31, confidence interval (CI) 95%, .18-0.56; P < .0001] and better leukemia-free survival (LFS) (HR = .62, CI 95%, .41-0.93; P = .023) compared to MRD positive pts. Non-relapse mortality (HR = 1.34, CI 95%, .68-2.62; P = .39) and acute graft versus host disease (HR = 1.09, CI 95%, .64-1.84; P = .78) were not significantly different between both groups. Similarly, overall survival (OS) (HR = .7, CI 95%, .44-1.12; P = .14) as well as graft versus host disease-free/relapse-free survival (HR = .71, CI 95%, .48-1.04; P = .078) were not significantly impacted by MRD status. Subset analysis for MRD positive pts revealed that pts with CMV+ donors experienced decreased relapse rates (HR = .32, CI 95%, .15-0.65; P = .001) as well as increased survival (HR = .37, CI 95%, .17-0.8; P = .012). No significant predictive factors for clinical outcome were identified in the MRD negative patient subset. A landmark analysis at 6 months (figure) suggests that the clinical benefit of pre-transplant MRD negativity in terms of relapse, OS, LFS, and GRFS is realized at this time point. Conclusion: MRD negativity at transplant is associated with a reduced relapse rate and improved LFS in AML patients undergoing T-cell replete haplo-SCT.